Abstract:Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on "event-driven" pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins. Unfortunately, PROTAC discovery is limited by warhead scarcity and laborious optimization campaigns. To address these shortcomings, analogous protein-based heterobifunctional degraders, known as bioPROTACs, have been developed. Compared to small-molecule PROTACs, bioPROTACs have higher success rates and are subject to fewer design constraints. However, the membrane impermeability of proteins severely restricts bioPROTAC deployment as a generalized therapeutic modality. Here, we present an engineered bioPROTAC template able to complex with cationic and ionizable lipids via electrostatic interactions for cytosolic delivery. When delivered by biocompatible lipid nanoparticles, these modified bioPROTACs can rapidly degrade intracellular proteins, exhibiting near-complete elimination (up to 95% clearance) of targets within hours of treatment. Our bioPROTAC format can degrade proteins localized to various subcellular compartments including the mitochondria, nucleus, cytosol, and membrane. Moreover, substrate specificity can be easily reprogrammed, allowing modular design and targeting of clinically-relevant proteins such as Ras, Jnk, and Erk. In summary, this work introduces an inexpensive, flexible, and scalable platform for efficient intracellular degradation of proteins that may elude chemical inhibition.

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Precise Modulation of Protein Degradation by Smart PROTACs

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

Reversible Assembly of Proteolysis Targeting Chimeras

Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Development of Stabilized Peptide-Based PROTACs Against Estrogen Receptor Α

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Targeted protein degradation: expanding the toolbox

PROTAC-induced Protein Structural Dynamics in Targeted Protein Degradation